136 related articles for article (PubMed ID: 18322392)
1. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease.
Uberti D; Lanni C; Racchi M; Govoni S; Memo M
Neurodegener Dis; 2008; 5(3-4):209-11. PubMed ID: 18322392
[TBL] [Abstract][Full Text] [Related]
2. Conformationally altered p53: a novel Alzheimer's disease marker?
Lanni C; Racchi M; Mazzini G; Ranzenigo A; Polotti R; Sinforiani E; Olivari L; Barcikowska M; Styczynska M; Kuznicki J; Szybinska A; Govoni S; Memo M; Uberti D
Mol Psychiatry; 2008 Jun; 13(6):641-7. PubMed ID: 17684496
[TBL] [Abstract][Full Text] [Related]
3. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients.
Uberti D; Lanni C; Carsana T; Francisconi S; Missale C; Racchi M; Govoni S; Memo M
Neurobiol Aging; 2006 Sep; 27(9):1193-201. PubMed ID: 16165254
[TBL] [Abstract][Full Text] [Related]
4. P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients.
Zhou X; Jia J
Neurosci Lett; 2010 Jan; 468(3):320-5. PubMed ID: 19914341
[TBL] [Abstract][Full Text] [Related]
5. Changes of p53 in the brains of patients with Alzheimer's disease.
Kitamura Y; Shimohama S; Kamoshima W; Matsuoka Y; Nomura Y; Taniguchi T
Biochem Biophys Res Commun; 1997 Mar; 232(2):418-21. PubMed ID: 9125193
[TBL] [Abstract][Full Text] [Related]
6. Alteration of protein kinase C conformation in red blood cells: a potential marker for Alzheimer's disease but not for Parkinson's disease.
Janoshazi A; Sellal F; Marescaux C; Danion JM; Warter JM; de Barry J
Neurobiol Aging; 2006 Feb; 27(2):245-51. PubMed ID: 15893856
[TBL] [Abstract][Full Text] [Related]
7. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers.
Tan M; Wang S; Song J; Jia J
Neurosci Lett; 2012 May; 516(2):226-31. PubMed ID: 22503900
[TBL] [Abstract][Full Text] [Related]
8. An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin.
Khan TK; Alkon DL
Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13203-7. PubMed ID: 16920798
[TBL] [Abstract][Full Text] [Related]
9. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease.
Buizza L; Cenini G; Lanni C; Ferrari-Toninelli G; Prandelli C; Govoni S; Buoso E; Racchi M; Barcikowska M; Styczynska M; Szybinska A; Butterfield DA; Memo M; Uberti D
PLoS One; 2012; 7(1):e29789. PubMed ID: 22242180
[TBL] [Abstract][Full Text] [Related]
10. Increased CD44 gene expression in lymphocytes derived from Alzheimer disease patients.
Uberti D; Cenini G; Bonini SA; Barcikowska M; Styczynska M; Szybinska A; Memo M
Neurodegener Dis; 2010; 7(1-3):143-7. PubMed ID: 20197694
[TBL] [Abstract][Full Text] [Related]
11. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.
Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C
Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
[TBL] [Abstract][Full Text] [Related]
14. Immune blood biomarkers of Alzheimer disease patients.
Avagyan H; Goldenson B; Tse E; Masoumi A; Porter V; Wiedau-Pazos M; Sayre J; Ong R; Mahanian M; Koo P; Bae S; Micic M; Liu PT; Rosenthal MJ; Fiala M
J Neuroimmunol; 2009 May; 210(1-2):67-72. PubMed ID: 19329192
[TBL] [Abstract][Full Text] [Related]
15. Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients.
Pitto M; Raimondo F; Zoia C; Brighina L; Ferrarese C; Masserini M
Neurobiol Aging; 2005 Jun; 26(6):833-8. PubMed ID: 15718041
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
17. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
Taniguchi M; Okayama Y; Hashimoto Y; Kitaura M; Jimbo D; Wakutani Y; Wada-Isoe K; Nakashima K; Akatsu H; Furukawa K; Arai H; Urakami K
Dement Geriatr Cogn Disord; 2008; 26(2):117-22. PubMed ID: 18654083
[TBL] [Abstract][Full Text] [Related]
18. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
19. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease.
Muck-Seler D; Presecki P; Mimica N; Mustapic M; Pivac N; Babic A; Nedic G; Folnegovic-Smalc V
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1226-31. PubMed ID: 19602426
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
